KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Receivables (2020 - 2022)

Vir Biotechnology (VIR) has disclosed Receivables for 3 consecutive years, with $7.0 million as the latest value for Q2 2022.

  • Quarterly Receivables changed N/A to $7.0 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Jun 2022, changed N/A year-over-year, with the annual reading at $773.1 million for FY2021, N/A changed from the prior year.
  • Receivables hit $7.0 million in Q2 2022 for Vir Biotechnology, down from $1.2 billion in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.2 billion in Q1 2022 to a low of $3.8 million in Q2 2020.
  • Historically, Receivables has averaged $387.5 million across 3 years, with a median of $159.0 million in 2021.
  • Biggest YoY gain for Receivables was 443.63% in 2022; the steepest drop was 443.63% in 2022.
  • Year by year, Receivables stood at $3.8 million in 2020, then skyrocketed by 20244.18% to $773.1 million in 2021, then plummeted by 99.09% to $7.0 million in 2022.
  • Business Quant data shows Receivables for VIR at $7.0 million in Q2 2022, $1.2 billion in Q1 2022, and $773.1 million in Q4 2021.